Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4128356
Max Phase: Preclinical
Molecular Formula: C31H33N5O4S2
Molecular Weight: 603.77
Molecule Type: Small molecule
Associated Items:
ID: ALA4128356
Max Phase: Preclinical
Molecular Formula: C31H33N5O4S2
Molecular Weight: 603.77
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: N=C(N)c1cccc(C[C@H](NS(=O)(=O)c2ccc3ccccc3c2)C(=O)N2CCCC(C(=O)NCc3cccs3)C2)c1
Standard InChI: InChI=1S/C31H33N5O4S2/c32-29(33)24-9-3-6-21(16-24)17-28(35-42(39,40)27-13-12-22-7-1-2-8-23(22)18-27)31(38)36-14-4-10-25(20-36)30(37)34-19-26-11-5-15-41-26/h1-3,5-9,11-13,15-16,18,25,28,35H,4,10,14,17,19-20H2,(H3,32,33)(H,34,37)/t25?,28-/m0/s1
Standard InChI Key: PIFQUSTVOQWPJQ-NMXAJACMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 603.77 | Molecular Weight (Monoisotopic): 603.1974 | AlogP: 3.63 | #Rotatable Bonds: 10 |
Polar Surface Area: 145.45 | Molecular Species: BASE | HBA: 6 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 10.02 | CX Basic pKa: 11.47 | CX LogP: 2.96 | CX LogD: 1.05 |
Aromatic Rings: 4 | Heavy Atoms: 42 | QED Weighted: 0.16 | Np Likeness Score: -1.64 |
1. Pant SM, Mukonoweshuro A, Desai B, Ramjee MK, Selway CN, Tarver GJ, Wright AG, Birchall K, Chapman TM, Tervonen TA, Klefström J.. (2018) Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform., 61 (10): [PMID:29701962] [10.1021/acs.jmedchem.7b01698] |
2. Steinmetzer T, Pilgram O, Wenzel BM, Wiedemeyer SJA.. (2020) Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding., 63 (4): [PMID:31658420] [10.1021/acs.jmedchem.9b01060] |
Source(1):